© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Ezetimibe started to draw global attention in the late 1990s as researchers searched for new ways to lower cholesterol without the familiar baggage of muscle pain that often comes with statins. Its discovery came through a combination of chance observation and determined screening for molecules that could block cholesterol absorption in the intestine. The industry soon focused on perfecting the synthetic route for each step of the ezetimibe molecule, with Intermediate 2 standing out as a milestone product in this multi-step chain. Over the years, different chemists rolled out modifications, not just to save money but to bump up yields and steer clear of byproducts. Ezetimibe's rise to market shows how global demand and careful intellectual property maneuvering shaped the ongoing chemistry work behind its key intermediates.
Intermediate 2 sits at a crucial crossroad during the synthesis of ezetimibe. It’s more than just a step—this molecule holds the right chemical handles for moving ahead into the next critical couplings in the pathway. Producers need it in high purity because even small contaminants can trip up subsequent steps and mess with the final drug’s quality. From years working in pharmaceutical labs, I’ve seen how much trust chemical suppliers need to build when providing these intermediates. Without precise Intermediate 2, everything downstream slows down or fails entirely. This puts constant pressure on research labs and manufacturers to tighten up both the science and business behind this product.
Ezetimibe Intermediate 2 stands out due to its particular structure. Its crystalline form gives it certain handling advantages in the lab, and the solid’s melting point stays within a tight range, providing a quick check for purity. It typically shows a white-to-off-white color, which means any discoloration often signals impurity or improper handling. The compound’s solubility in common organic solvents like dichloromethane and acetonitrile makes it manageable for reaction and purification work. Chemically, the molecule shows decent stability against air and light, though careless exposure still risks slow degradation by hydrolysis. Spectral signatures picked out by proton NMR, carbon NMR, and IR offer clear fingerprints for regulatory filings or batch-release testing. This level of transparency is key in pharma, where regulatory bodies demand clear evidence for identity and purity.
Producers ship Intermediate 2 with thorough documentation. Any laboratory or manufacturer gets a certificate of analysis detailing assay, specific rotation, impurities, water content, and residual solvents. Strict batch numbering and full chain-of-custody records let buyers track origin. Product labels stick to chemical naming rules and often include the structure for clarity. Most suppliers also include hazard statements covering irritant risks and safe storage conditions, which helps minimize workplace accidents. Industry standards push for 99 percent purity or higher, knowing even low-level contaminants sometimes survive purification of drug substances. These technical guardrails stem from years of regulatory experience and help maintain trust between buyers, suppliers, and, most importantly, patients.
Manufacturing Intermediate 2 leans heavily on protecting-group chemistry and precise coupling reactions. The early step involves building the main carbon skeleton, then layering in aromatic rings through selectively activated bonds. Chemists need tight temperature and solvent control since small environmental shifts can trigger unintended side reactions or loss of product. I’ve watched teams debate the best choice between liquid or solid-phase reagents to coax every last bit of value from each raw material, especially as global prices swing up and down. Overall, the route involves between three and five distinct chemical transformations, each one needing careful purification by crystallization or chromatography. Manufacturing teams keep a close eye on mother liquors and filtrates to catch recycled material or early signs of trouble. The skills developed refining these steps often lead to successful technology transfer across continents as companies race to meet global demand.
Beyond the classic route, many researchers have poked at the core molecule, hoping to find shortcuts or greener chemistry. Scientists experiment with milder oxidants, swap out harmful chlorinated solvents, and try enzymatic reactions to lower the energy bills and waste output of traditional methods. In journals and at conferences, researchers showcase clever alternatives like microwave-assisted couplings or aqueous organic phase reactions, cutting run times from several hours to just minutes. These modifications often spark heated debate, since a few degrees of temperature or drops of solvent can change outcomes on the scale of tons per year. Regulatory teams also force innovation since each new impurity or byproduct must be studied for toxicity and residual carryover. The wider field of pharmaceutical intermediates gradually benefits from these innovations, carrying new process ideas into unrelated drug projects.
Intermediate 2 goes by several aliases in scientific publications, depending on local naming customs or which company’s catalog you read. You’ll hear it called “Ezetimibe Core Intermediate,” “Key Intermediate 2 for Ezetimibe,” or just “Intermediate B” in some dry-erase board meetings. Its IUPAC name often pops up in regulatory filings, paired with CAS numbers to avoid error. Major chemical suppliers use proprietary batch codes to prevent confusion in shipping and customs, especially when sourcing across borders. Synonyms can cause headaches for less-experienced buyers, so stakeholders agree clear naming and structure everywhere in the documentation help save time and money during audits or inspections.
Careless handling of Intermediate 2 can spark trouble, despite its low acute toxicity. Many forms of the compound dust easily, irritating skin and eyes or contaminating shared work spaces. I’ve seen labs invest heavily in ventilation and personal protection after one small slip caused eye irritation and forced a plant shutdown for cleaning. Standard practice in chemical plants now includes gloves, goggles, and dust masks for anyone who might handle even small samples. Regulations in Europe and North America demand full Material Safety Data Sheets with hazard pictograms, response measures, and incident reporting forms. Regular safety drilling keeps plant staff sharp should a fire or accidental spill occur. Waste disposal routes must comply with environmental law to keep intermediate residues out of public water supplies. The industry’s move toward green chemistry also puts pressure on suppliers to switch to recyclable containers and more benign solvents.
The entire production of Intermediate 2 flows into one main outlet: the manufacture of ezetimibe, the active ingredient in cholesterol-lowering pills prescribed to millions worldwide. No alternative route to the finished drug skips over this intermediate, so security of its supply shapes pharma’s confidence in delivering ezetimibe on schedule. Alongside that, academic groups sometimes use it as a chemical teaching tool or as a scaffold for new research into absorption inhibitors. Clinical interest in cholesterol and lipid metabolism keeps the scientific spotlight on this chemistry, with questions about new analogs or modified drugs often starting with manipulation of this intermediate.
Lab groups in the US, Europe, and Asia keep pushing for better yields and shorter routes to Intermediate 2. Some teams focus on tweaking catalysts, while others build out new analytics to track and pin down tiny byproduct levels. Universities often publish improvements targeting greener solvents or automated synthesis, and pharmaceutical giants quietly bankroll process improvements meant to save millions in bulk production. Much of this progress builds from trial and error, with chemists racing to patent incremental process improvements before competitors do the same. From my own experience, successful technology transfer from R&D to plant floor depends not just on discovery, but on detailed handover documentation and patient training of operators who’ll be making tons of material each month. Industry knowledge spreads when scientists move from company to company, carrying tried-and-true tips alongside cutting-edge ideas.
Industry regulators and drug makers can’t afford to overlook even minor toxicity risks from compounds like Intermediate 2. Preclinical testing screens for acute toxicity, skin and eye irritation, long-term carcinogenicity, and any breakdown products that could accumulate in the environment. The compound’s low dose handling means only small spills risk acute symptoms, but chronic exposure scenarios push regulatory teams to set occupational limits and regular air-monitoring in production environments. Research shows limited risk to the public thanks to containment and disposal controls, but plant workers stay vigilant about minimizing exposure and washing up post-shift. Ongoing research into green chemistry hopes to cut hazards further by switching to milder reagent systems and less volatile solvents, with the dual benefit of saving costs and shrinking safety incidents.
Looking forward, there’s every reason to believe Ezetimibe Intermediate 2 will remain an industrial staple as population aging and heart disease drive demand higher for cholesterol-lowering therapies. Chemical engineers stand to win by adopting continuous-flow production tools, which drop per-unit cost and limit batch-to-batch variation. Ongoing academic research points toward enzymatic synthesis and biosynthesis, which could someday undercut traditional routes in both economics and sustainability. Meanwhile, ongoing regulatory tightening and environmental scrutiny keep all eyes on process waste and workplace risk. Real success will rest with those companies that combine production scale-up know-how with the nimbleness to pivot as new science or law shakes up familiar routines. With cholesterol metabolism under heavy research and new drug combinations on the horizon, Intermediate 2’s value shows no sign of fading from pharma’s playbook.
Anyone watching the news on cholesterol control might not hear the term “Ezetimibe Intermediate 2.” The public often sees discussions about high cholesterol, statins, or Ezetimibe itself as a finished drug. Yet, every tablet of Ezetimibe comes from a long chain of steps, and Intermediate 2 plays a core part in that journey. This chemical sits right in the middle of Ezetimibe synthesis, shaping how the end medicine works and what it costs to bring to patients.
Pharmaceutical labs count on reliable building blocks. Intermediate 2 forms as an important checkpoint during Ezetimibe production. If laboratories rush this step or use poor-quality materials, patients end up at the short end of the stick. The importance of consistency in the production of each intermediate step cannot be overstated if safety and purity of medicine in the final pill is the goal. Doctors prescribe Ezetimibe to block cholesterol from being absorbed by the gut. Patients who cannot tolerate statins depend even more on getting a dependable dose every time. Without quality Intermediate 2, the whole supply chains takes a hit, affecting global access to Ezetimibe.
As a writer covering both science and public health, it strikes me how much trouble can begin long before a patient sees a box at the pharmacy. Making Ezetimibe means executing multiple chemical reactions, each with risks for residue or by-products. Intermediate 2’s purity defines how tough it will be to get a clean, final medicine. Any mix-ups here can double downstream work or even create shortages. In the past, supply chain splits between different countries have left manufacturers scrambling when demand for cholesterol drugs rises.
This isn’t just an industrial headache. High cholesterol drives risks for heart attacks and strokes. For many, Ezetimibe remains a backup plan after statins. Interruptions in the supply of a vital intermediate sends ripples down the supply chain, threatening outcomes for patients on tight budgets or living in countries with few suppliers. Regulators like the US FDA step in to check methods and materials every step of the way because cutting corners simply means higher risk later.
Solving these bottlenecks calls for investment from several directions. Engineers in chemical synthesis can look for greener, cleaner routes that cut waste or improve yield for Intermediate 2. Contract manufacturers with experience in quality control help keep standards tight. Ready access to reliable, high-purity intermediates reduces late-stage recalls and price shocks that hurt patients. More companies with technology and expertise in producing this crucial step mean fewer stories of drug shortages.
Open reporting, transparency, and audits by public agencies keep profit-driven shortcuts in check. Researchers in both academia and industry have the chance to rethink how Intermediate 2 gets produced, from the solvents down to waste products. The effort may not grab headlines, but the end result—low-cost, effective medicine for millions—shows why these back-end processes must get as much attention as front-page drug launches.
By valuing each stage of drug development, especially the hard-to-pronounce intermediates, society helps make sure treatments don’t just exist but actually reach everyone who needs them. Ezetimibe Intermediate 2 reminds us that the real work in healthcare relies just as much on what happens in quiet lab benches as what gets shown in TV ads.
Ezetimibe blocks cholesterol absorption in the intestine. Behind every successful batch of this medicine lies a handful of important chemical building blocks. One of them, often called Ezetimibe Intermediate 2, draws serious attention for anyone involved in pharmaceutical manufacturing. The structure of this compound, and how chemists produce it, isn’t hidden behind trade secrets; it’s a lynchpin for safety, consistency, and compliance.
Let’s break it down. Ezetimibe Intermediate 2, typically known in industry circles as (3R,4S)-3-(4-fluorophenyl)-1-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)azetidin-2-one, rests on a four-membered lactam ring. Attached to this ring, you’ll find three key side chains at specific positions. The main ring, known as azetidin-2-one, brings rigidity, helping lock each substituent in the specific orientation this pathway demands.
One group features a para-fluorophenyl moiety. This fluorine atom on the phenyl ring doesn’t just tweak the molecule’s chemical behavior; it shapes the metabolic pathway, ensuring the active drug later works as it should. The two other groups—a pair of para-hydroxyphenyl rings—bring the potential for hydrogen bonding. Strong hydrogen-bonding helps give ezetimibe itself its cholesterol-blocking effect, and the presence here guides purity and reactivity in every synthetic step.
Regulatory agencies want the right molecule in the bottle, no more and no less. If impurities slip in, trouble follows quickly. From a hands-on perspective, I’ve watched colleagues try to salvage batches with subtle side-product contamination. It rarely ends well. Minor slip-ups in stereochemistry—the exact 3D arrangement of those substituents—tank yield, compromise safety, and create quality headaches.
The structure of Ezetimibe Intermediate 2 sets the stage for the next phase of synthesis. Suppose a batch goes off-track at this step. The entire process downstream—final transformation, purification, and tablet formation—loses reliability. At one site I worked, just a missing hydroxyl group on an intermediate forced shutdown, recalled shipments, and costly upgrades. This gives a real-world lesson: chemical integrity matters at every step.
Pharmaceutical plants focus on a handful of points to nail down this chemical structure. Analytical tools like NMR spectroscopy and HPLC check for the correct stereochemistry and rule out unwanted bits. Process engineers push for robust, repeatable conditions that don’t tempt chance: controlled temperature, well-chosen solvents, and precisely metered reagents. Skimping on these details might look tempting under cost pressure, but long-term everyone loses—factories, regulators, and, most importantly, patients.
Some technology updates help chemists avoid headaches here. For example, modern chiral catalysts create just the desired isomer, cutting down clean-up costs and batch failures. Automated feedback loops monitor every reaction. If a slight deviation pops up, the system pauses, flags the deviation, and brings in human eyes. These checks keep Ezetimibe Intermediate 2 in tight spec.
Every tiny decision around Ezetimibe Intermediate 2 echoes through the entire system. It’s not a vague or academic exercise. Accuracy and attention at the chemical structure level directly determine whether the finished medicine helps cholesterol patients without new safety risks. A smart approach—combining old-school hands-on vigilance with new tools—keeps both science and trust intact. That’s where effective medicine begins, not just in labs, but in lives lived a little healthier as a result.
Ezetimibe shows up in prescription bottles across the globe, helping people lower their cholesterol and fend off serious heart trouble. Medicines like this don't land on pharmacy shelves fully formed—just as a house comes together brick by brick, active pharmaceutical ingredients come from smaller, carefully crafted chemical building blocks. One of those building blocks for ezetimibe, known in the lab as Intermediate 2, plays a crucial role in the whole process.
Manufacturers begin with simple, off-the-shelf chemicals: usually a chlorinated aromatic compound, a nitrile derivative, and some common solvents. Skilled synthetic chemists select these materials based on their purity and reliability, since any slip here can mean trouble later. Controlling the source and quality at this first stage is fundamental, helping to ensure the drug eventually does its job as intended.
Intermediate 2 doesn't spring into existence just by combining things in a beaker. It takes a careful series of chemical reactions, each backed by decades of research. The backbone usually starts as a substituted benzene. Chemists introduce the necessary functionalities using methods like Friedel-Crafts acylation—this step attaches new groups to the aromatic ring, setting the framework for future changes. Precision here means fewer side-products and a cleaner intermediate down the line.
Next, the process may move on to reduction reactions. These steps break tough chemical bonds or transform one group into another, often under precise temperature and pressure. Any mistake leads to unwanted impurities or wasted material. Quality teams monitor every step, not letting a batch move forward unless it meets strict industry standards.
It's rare for chemical intermediates to come out perfectly clean right away. After each reaction, the crude mixture contains the target compound along with traces of solvents, byproducts, and leftover reactants. Technicians use methods like crystallization, extraction, and chromatography to draw out only what they need. Each approach involves trade-offs: crystallization offers speed, while chromatography might catch hidden impurities that could cause problems downstream.
Some of these chemical reactions generate heat or use hazardous reagents. Workers rely on enclosed reactors, proper ventilation, special gloves, and well-tested procedures to keep themselves safe and prevent harmful leaks. Facilities with solid environmental records often reclaim solvents, treat waste with neutralizing agents, and send used reactants for secure disposal. Regulatory agencies don't take shortcuts; inspectors check that manufacturers follow rules every time.
Before moving forward, batches of Intermediate 2 undergo a series of tests. Analysts use tools like HPLC and NMR—these acronyms stand for machines that spot even tiny traces of impurities. Only pure, predictable batches move on, helping protect the patients who eventually rely on the finished medicine.
Classic chemistry methods set the foundation, but the field still evolves. Recent advances in green chemistry use milder reagents and cut down on hazardous waste. Automation takes guesswork out of scale-up, while digital controls let teams react quickly to any blip in quality. Each upgrade strengthens trust in the medicines many depend on.
Lab work over the years has shown me the consequences of skipping over proper storage practices. With Ezetimibe Intermediate 2, every step counts. This compound doesn’t just represent a link in a production chain—it’s a safeguard for patient health. Few things frustrate scientists more than a ruined batch due to a preventable storage slip-up. Chemicals like this one call for a mix of vigilance and respect for their quirks.
For Ezetimibe Intermediate 2, temperature swings pose one of the biggest threats to stability. Most producers, including reputable pharmaceutical companies, recommend a cool, controlled space—typically between 2 °C and 8 °C. Anything outside this range raises the risk of degradation. I remember rescuing a shipment that had missed this basic point: it had sat in a loading bay for two days, and by the time we ran the next analysis, purity levels had dropped. It’s easy to overlook, but even a few hours of exposure to heat or direct sunlight can ruin a lot of hard work.
Humidity remains one of the stealthiest culprits. Ezetimibe intermediates tend to attract water. Over time, unchecked moisture can spark unwanted chemical reactions, making the material less reliable for downstream synthesis. Air-tight containers with desiccants make a real difference. Too many labs cut corners with container seals. Investing in proper sealing equipment has saved me more headaches than I care to remember.
Direct light weakens many chemicals, and this intermediate falls into that group. Storage in amber bottles or opaque containers prevents photo-degradation. I’ve met techs who thought covering shelves with brown paper would suffice, but light finds its way in unless you use the right barriers. Keeping storage areas away from windows and using minimal wattage lighting adds another layer of protection most overlook.
Clean storage spaces seem obvious but often get neglected once deadlines loom. Chemical residues or dust lead to contamination, skewing results or spoiling whole batches. Setting up routine cleaning schedules and clear labeling works far better than hoping someone will “get to it later.” In one of my previous labs, a mislabeled bottle caused a cascade of confusion traced back to contaminated glassware. Simple process tweaks, like using dedicated containers for intermediates, kept mistakes from repeating.
It’s tempting to cut corners under pressure, but good storage habits cost less than fixing lost batches. Reliable temperature monitoring—digital thermometers with data loggers—provides peace of mind. Regular audits create accountability. Team training ensures everyone knows what’s at stake. When suppliers provide precise guidance and labs actually follow those guidelines, the process delivers more consistent, high-quality products. Regulatory bodies also check storage logs, so keeping everything documented pays off beyond just good science.
In my experience, treating every chemical with the attention it deserves saves time, money, and reputation. Anyone serious about quality can build these habits into their workflow—small changes mean fewer failures and stronger trust from those who count on the end product.
Ezetimibe plays a big role in controlling cholesterol, and its production leans heavily on reliable access to intermediates. Intermediate 2, also called methyl 4-chloro-3-oxobutanoate, ranks high among the most sought-after precursors for the main active pharmaceutical ingredient. Anyone keeping up with trends in pharmaceutical manufacturing has seen growing questions about supply, safety, and regulatory hurdles connected to key intermediates like this one.
In my years working closely with life sciences and supply chain teams, wholesale access to intermediates has never followed a simple path. Regulatory controls keep suppliers on their toes. China, India, and several European firms lead the way as source countries. If you call around or search reputable trade platforms, many lab-scale and pilot-scale suppliers offer Ezetimibe Intermediate 2 in moderate lots. Scaling to hundreds of kilograms, though, quickly exposes supply gaps. Much of the time, the largest manufacturers want guaranteed repeat orders for such volumes, not just a one-off sale.
I remember sitting with a pharmaceutical procurement manager who spent weeks sifting through vendor qualifications and GMP certifications just to get approval on intermediates sourced abroad. Audits, certificate checks, and process transparency matter. A lot of the hesitation boils down to trust—nobody wants to get stuck with a tainted batch, which can throw a whole production run into question.
Documents alone won’t build confidence. I’ve seen QC labs in India and Europe tackle strict testing, offering high-end HPLC and purity data. Still, even with shiny paperwork and perfect specs, buyers double-check through third-party labs, especially for bulk purchases. The need for chain-of-custody is more than paperwork; it’s about reputational risk, and failing a batch release pushes costs up fast.
Safety is another dimension. Handling and storing bulk intermediates—often combustible or prone to degradation—demands trained staff and well-maintained facilities. Lax storage means lost value, lost time, or at worst, product recalls. Having spent time in labs where chemicals are packed floor-to-ceiling, I can say bulk handling logistics soon dominate the conversation, not just price and purity.
Big buyers usually form relationships with a shortlist of trusted sources. They visit plants, meet with quality heads, and put clear contractual requirements in place. Lower-volume buyers or those newly entering API manufacturing tend to struggle more. Open platforms like Alibaba offer introductions to vendors but often come with noise—fly-by-night brokers, quality roulette, and opaque pricing. So, direct contact with established manufacturers, reference checks, and conversations around batch samples remain crucial.
One clear path I’ve seen work involves choosing an experienced third-party sourcing partner. These intermediaries watch quality, root out supply chain risks, and back their recommendations with results. They might add a price markup, but the stability and risk reduction outweigh the upfront margin. For anyone venturing into regular bulk orders, investing in robust supply chain checks and leveraging certification audits pays off.
Bulk supply of Ezetimibe Intermediate 2 sits at the intersection of transparency, technical rigor, and reliable logistics. Getting it right means aligning with reputable suppliers, committing to checks beyond the basics, and never underestimating the demands of handling chemicals at scale.
| Names | |
| Preferred IUPAC name | (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one |
| Other names |
Ezetimibe Impurity 2 4-(4-Chlorobenzoyl)phenol |
| Pronunciation | /ɛˈzɛtɪmiːb ˌɪntərˈmiːdiət tuː/ |
| Identifiers | |
| CAS Number | 163222-33-1 |
| Beilstein Reference | 1305076 |
| ChEBI | CHEBI:142487 |
| ChEMBL | CHEMBL2338888 |
| ChemSpider | 23470015 |
| DrugBank | DB00973 |
| ECHA InfoCard | 100.235.042 |
| EC Number | 2219891-22-5 |
| Gmelin Reference | Gmelin Reference 832926 |
| KEGG | C16197 |
| MeSH | Ezetimibe Intermediate 2"[Supplementary Concept] |
| PubChem CID | 10486527 |
| RTECS number | UJ9TZ2C6EZ |
| UNII | 21U3O14GQS |
| UN number | UN-2811 |
| CompTox Dashboard (EPA) | Ezetimibe Intermediate 2 CompTox Dashboard (EPA) identifier string is: **DTXSID5076377** |
| Properties | |
| Chemical formula | C22H20ClNO3 |
| Molar mass | 409.52 g/mol |
| Appearance | White to off-white solid |
| Odor | Odorless |
| Density | 1.17 g/cm3 |
| Solubility in water | Slightly soluble in water |
| log P | 2.9 |
| Vapor pressure | 0.0 mmHg at 25°C |
| Acidity (pKa) | 7.82 |
| Basicity (pKb) | 10.72 |
| Magnetic susceptibility (χ) | -7.1×10^-6 cm³/mol |
| Refractive index (nD) | 1.538 |
| Dipole moment | 2.50 D |
| Pharmacology | |
| ATC code | C10AX09 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. Causes skin irritation. |
| GHS labelling | GHS05: Corrosion, GHS07: Exclamation mark |
| Signal word | Warning |
| Hazard statements | H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | P264, P270, P301+P312, P330, P501 |
| NFPA 704 (fire diamond) | 1-2-0 |
| Flash point | >100°C |
| NIOSH | Not Listed |
| REL (Recommended) | 2 years |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Ezetimibe Ezetimibe Intermediate 1 Ezetimibe Intermediate 3 Ezetimibe Impurity A Ezetimibe Impurity B |
